Anavex Life Sciences Corp (AVXL)

[XenaLives]

The company has stated Q3 2020 for end of study.

A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease
Occurring Dates:
05/07/2018 to 30/07/2020
Participant Duration:
12 months
State of study:
New South Wales
Queensland
South Australia
Western Australia
Victoria

Overview:
Anavex Life Sciences is seeking volunteers to participate in a new clinical trial for people with mild Alzheimer's disease. ANAVEX2-73 is a small molecule that has shown in research studies to improve mental activities that are involved in learning, remembering and using general daily knowledge. These results are associated with ANAVEX2-73 possibly having protective properties on the brain neurons (brain nerve cells) that are usually damaged in Alzheimer’s disease. It is thought that ANAVEX2-73 acts by attaching to and activating specific proteins called “survival receptors” and this may enable ANAVEX2-73 to modify the disease.

Participation in this study will involve taking a daily oral tablet (ANAVEX2-73 or placebo) and visiting a research centre for 8 study appointments over a 48 week period. To be eligible to participate, participants must be:

Between 60 and 85 years of age
Have a diagnosis of mild Alzheimer's disease
Have a study partner able attend study appointments
Can read and converse in English
Further Information:
If you think this sounds interesting and would like to know more, please register your details at www.anavexaustralia.com or phone [phone].

This research has been approved by St Vincents Hospital (Melbourne) Ethics Committee (Project Number: 123/18).

Full Name:
A/Prof Stephen Macfarlane
Institute:
HammondCare
Email:
[e-mail]
Phone Number:
[phone]

https://www.dementia.org.au/research/participate/study/a-phase-2b3-double-blind-randomized-placebo-controlled-48-week-safety-and-efficacy-trial-of-anavex2-73-for-the-treatment-of-early-alzheimer%E2%80%99s-disease